MiR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer

British Journal of Cancer

Volumn 102, Issue 5, 2010, Pages 883-891

  Chiyomaru, T ^a   Enokida, H ^a   Tatarano, S ^a   Kawahara, K ^b   Uchida, Y ^a   Nishiyama, K ^a   Fujimura, L ^c   Kikkawa, N ^c   Seki, N ^c   Nakagawa, M ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Kawahara Nephro urology Clinic   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Bladder cancer; FSCN1; MicroRNA; MiR 133a; MiR 145

Indexed keywords

ACTIN BINDING PROTEIN; MATRIGEL; MICRORNA; PROTEIN FASCIN HOMOLOGUE 1; PROTEIN MIR 133A; PROTEIN MIR 145; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WOUND HEALING;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARRIER PROTEINS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LUCIFERASES; MALE; MICROFILAMENT PROTEINS; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 77649271930     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605570     Document Type: Article

References (50)

1. Adams JC, Clelland JD, Collett GD, Matsumura F, Yamashiro S, Zhang L (1999) Cell-matrix adhesions differentially regulate fascin phosphory-lation. Mol Biol Cell 10: 4177-4190
2. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, Garćia-Foncillas J (2006) Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5: 29
3. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, Belbin TJ, Schlecht NF (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736-745
4. Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA, Bismar TA (2009) Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 15: 1376-1383
5. Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, Zhou X, Jones PA (2009) The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69: 2623-2629
6. Goncharuk VN, Ross JS, Carlson JA (2002) Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 29: 430-438
7. Grothey A, Hashizume R, Ji H, Tubb BE, Patrick Jr CW, Yu D, Mooney EE, McCrea PD (2000) C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 19: 4864-4875
8. Hashimoto Y, Skacel M, Adams JC (2005) Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 37: 1787-1804
9. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N (2009) Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125: 345-352
10. Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, Farthing MJ, Pignatelli M, Adams JC (2003) Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 162: 69-80
11. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96
12. Karasavvidou F, Barbanis S, Pappa D, Moutzouris G, Tzortzis V, Melekos MD, Koukoulis G (2008) Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness. Arch Pathol Lab Med 132: 1912-1915
13. Kloosterman WP, Wienholds E, de Bruijn E, Kauppinen S, Plasterk RH (2006) In situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes. Nat Methods 3: 27-29
14. Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC (2002) Fascins, and their roles in cell structure and function. Bioessays 24: 350-361
15. Kwak C, Ku JH, Park JY, Lee E, Lee SE, Lee C (2004) Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. J Urol 171: 149-152
16. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294: 853-858
17. Lin CK, Chao TK, Yu CP, Yu MH, Jin JS (2009b) The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS 117: 162-175
18. Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, Huang L (2009a) MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol 181: 1372-1380
19. Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, DiRenzo J, Korc M, Cole CN, Bak M, Kauppinen S, Dmitrovsky E (2009) Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res 15: 1177-1183
20. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, Yeo CJ, Hruban RH (2003) Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16: 902-912
21. McCarthy JJ, Esser KA (2007) MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 102: 306-313
22. Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793
23. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
24. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, Sonzogni A, De Manzoni G, Terzi A, Durante E, Bresaola E, Pezzella F, Viale G (2003) Independent prognostic value of fascin immunoreactivity in stage I non-small cell lung cancer. Br J Cancer 88: 537-547
25. Qiu D, Katanoda K, Marugame T, Sobue T (2009) A joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer 124: 443-448
26. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava EM, Kosma VM (1999) Reduced expression of á catenin is associated with poor prognosis in colorectal carcinoma. J Clin Pathol 52: 10-16
27. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106: 3207-3212
28. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ, Kruhøffer M, Laurberg S, Kauppinen S, Ørntoft TF, Andersen CL (2008) Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416-6424
29. Schickel R, Boyerinas B, Park SM, Peter ME (2008) MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27: 5959-5974
30. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S, Cole CN (2007) Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620
31. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R (2007) Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590
32. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R (2007) Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colo-rectal cancer. Oncology 72: 397-402
33. Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumours, 6th edn. International Union Against Cancer (UICC). New York: Wiley-Liss. 199-202
34. Soukup V, Babjuk M, Dusková J, Pesl M, Szakáczová M, Zámecńik L (2008) Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma? Urol Int 80: 413-418
35. Sugimoto T, Seki N, Shimizu S, Kikkawa N, Tsukada J, Shimada H, Sasaki K, Hanazawa T, Okamoto Y, Hata A (2009) The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. Genes Chromosomes Cancer 48: 132-142
36. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA (2007) MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452
37. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y (2009) Decreased expression of microRNA-143 and-145 in human gastric cancers. Oncology 77: 12-21
38. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16: 206-216
39. Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J (2005) Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol 36: 741-766
40. van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47: 736-748
41. Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG (2006) Role of fascin in filopodial protrusion. J Cell Biol 174: 863-875
42. Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Laé M, Louvard D, Ben-Ze'ev A, Robine S (2007) Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 67: 6844-6853
43. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY, Sun XF (2009b) Clinicopathological significance of microRNA-31,-143 and-145 expression in colorectal cancer. Dis Markers 26: 27-34
44. Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, Zhou H, Zhao RC (2009a) miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 34: 1461-1466
45. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3: e2557
46. Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R, Ignace Wei W (2008a) Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 123: 251-257
47. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI (2008b) Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14: 2588-2592
48. Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, Yang ZM, Niu YD, Shen ZY, Li EM (2005) Role of fascin in the proliferation and invasive-ness of esophageal carcinoma cells. Biochem Biophys Res Commun 337: 355-362
49. Yang L, Bailey L, Baltimore D, Wang P (2006) Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci USA 103: 11479-11484
50. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Cai W, Niu Y, Yang Z, Shen Z, Li E (2006) Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma. J Clin Pathol 59: 958-964